{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:29:06Z","timestamp":1793910546861,"version":"4.8.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1038\/s41423-021-00683-y","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T07:05:51Z","timestamp":1620630351000},"page":"1425-1436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":137,"title":["RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor"],"prefix":"10.1038","volume":"18","author":[{"given":"Yun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianming","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3351-6420","authenticated-orcid":false,"given":"Rongbin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"key":"683_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev.immunol.021908.132715","volume":"27","author":"F Martinon","year":"2009","unstructured":"Martinon, F., Mayor, A. & Tschopp, J. The Inflammasomes: guardians of the Body. Annu. Rev. Immunol. 27, 229\u2013265 (2009).","journal-title":"Annu. Rev. Immunol."},{"key":"683_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1146\/annurev-immunol-031210-101405","volume":"29 29","author":"BK Davis","year":"2011","unstructured":"Davis, B. K., Wen, H. T. & Ting, J. P. Y. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu. Rev. Immunol. 29 29, 707\u2013735 (2011).","journal-title":"Annu. Rev. Immunol."},{"key":"683_CR3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev.pathol.4.110807.092239","volume":"4","author":"G Chen","year":"2009","unstructured":"Chen, G., Shaw, M. H., Kim, Y. G. & Nunez, G. NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev. Pathol.-Mech. 4, 365\u2013398 (2009).","journal-title":"Annu Rev. Pathol.-Mech."},{"key":"683_CR4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nri.2016.58","volume":"16","author":"P Broz","year":"2016","unstructured":"Broz, P. & Dixit, V. M. Inflammasomes: mechanism of assembly, regulation and signalling. Nat. Rev. Immunol. 16, 407\u2013420 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"683_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237\u2013241 (2006).","journal-title":"Nature"},{"key":"683_CR6","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/ni.1935","volume":"11","author":"SL Masters","year":"2010","unstructured":"Masters, S. L. et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat. Immunol. 11, 897\u2013904 (2010).","journal-title":"Nat. Immunol."},{"key":"683_CR7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/ni.2022","volume":"12","author":"H Wen","year":"2011","unstructured":"Wen, H. et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 12, 408\u2013415 (2011).","journal-title":"Nat. Immunol."},{"key":"683_CR8","doi-asserted-by":"crossref","unstructured":"Unamuno, X. et al. NLRP3 inflammasome blockade reduces adipose tissue inflammation and extracellular matrix remodeling. Cell Mol. Immunol. 18, 1045\u20131057 (2021).","DOI":"10.1038\/s41423-019-0296-z"},{"key":"683_CR9","doi-asserted-by":"crossref","unstructured":"He, Y. et al. Immunopathobiology and therapeutic targets related to cytokines in liver diseases. Cell Mol. Immunol. 18, 18\u201337 (2021).","DOI":"10.1038\/s41423-020-00580-w"},{"key":"683_CR10","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature11729","volume":"493","author":"MT Heneka","year":"2013","unstructured":"Heneka, M. T. et al. NLRP3 is activated in Alzheimer\u2019s disease and contributes to pathology in APP\/PS1 mice. Nature 493, 674\u2013678 (2013).","journal-title":"Nature"},{"key":"683_CR11","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","volume":"464","author":"P Duewell","year":"2010","unstructured":"Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357\u20131361 (2010).","journal-title":"Nature"},{"key":"683_CR12","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1136\/gut.2009.197822","volume":"59","author":"C Bauer","year":"2010","unstructured":"Bauer, C. et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 59, 1192\u20131199 (2010).","journal-title":"Gut"},{"key":"683_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.immuni.2010.03.003","volume":"32","author":"MH Zaki","year":"2010","unstructured":"Zaki, M. H. et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 32, 379\u2013391 (2010).","journal-title":"Immunity"},{"key":"683_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev-cellbio-101011-155745","volume":"28","author":"M Lamkanfi","year":"2012","unstructured":"Lamkanfi, M. & Dixit, V. M. Inflammasomes and their roles in health and disease. Annu Rev. Cell Dev. Biol. 28, 137\u2013161 (2012).","journal-title":"Annu Rev. Cell Dev. Biol."},{"key":"683_CR15","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1074\/jbc.M113.515080","volume":"289","author":"Y He","year":"2014","unstructured":"He, Y. et al. 3,4-Methylenedioxy-beta-nitrostyrene Inhibits NLRP3 Inflammasome Activation by Blocking Assembly of the Inflammasome. J. Biol. Chem. 289, 1142\u20131150 (2014).","journal-title":"J. Biol. Chem."},{"key":"683_CR16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm.3806","volume":"21","author":"RC Coll","year":"2015","unstructured":"Coll, R. C. et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21, 248\u2013255 (2015).","journal-title":"Nat. Med."},{"key":"683_CR17","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1084\/jem.20171419","volume":"214","author":"H Jiang","year":"2017","unstructured":"Jiang, H. et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J. Exp. Med. 214, 3219\u20133238 (2017).","journal-title":"J. Exp. Med."},{"key":"683_CR18","doi-asserted-by":"crossref","unstructured":"Huang, Y. et al. Tranilast directly targets NLRP3 to treat inflammasome-driven diseases. EMBO Mol. Med. 10, e8689 (2018).","DOI":"10.15252\/emmm.201708689"},{"key":"683_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04947-6","volume":"9","author":"H He","year":"2018","unstructured":"He, H. et al. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat. Commun. 9, 2550 (2018).","journal-title":"Nat. Commun."},{"key":"683_CR20","doi-asserted-by":"publisher","first-page":"E1530","DOI":"10.1073\/pnas.1716095115","volume":"115","author":"C Marchetti","year":"2018","unstructured":"Marchetti, C. et al. OLT1177, a beta-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc. Natl Acad. Sci. USA 115, E1530\u2013E1539 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"683_CR21","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","volume":"15","author":"RC Coll","year":"2019","unstructured":"Coll, R. C. et al. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat. Chem. Biol. 15, 556\u2013559 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"683_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/d41573-019-00086-9","volume":"18","author":"A Mullard","year":"2019","unstructured":"Mullard, A. NLRP3 inhibitors stoke anti-inflammatory ambitions. Nat. Rev. Drug Disco. 18, 405\u2013407 (2019).","journal-title":"Nat. Rev. Drug Disco."},{"key":"683_CR23","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S2665-9913(20)30065-5","volume":"2","author":"V Kluck","year":"2020","unstructured":"Kluck, V. et al. Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. Lancet Rheumatol. 2, e270\u2013e280 (2020).","journal-title":"Lancet Rheumatol."},{"key":"683_CR24","first-page":"173","volume":"21","author":"B Oronsky","year":"2016","unstructured":"Oronsky, B. et al. Rockets, radiosensitizers, and RRx-001: an origin story part I. Disco. Med 21, 173\u2013180 (2016).","journal-title":"Disco. Med"},{"key":"683_CR25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.tranon.2015.12.003","volume":"9","author":"MM Kim","year":"2016","unstructured":"Kim, M. M. et al. Whole brain radiotherapy and RRx-001: two partial responses in radioresistant melanoma brain metastases from a phase I\/II clinical trial: a TITE-CRM phase I\/II clinical trial. Transl. Oncol. 9, 108\u2013113 (2016).","journal-title":"Transl. Oncol."},{"key":"683_CR26","doi-asserted-by":"crossref","unstructured":"Carter, C. et al. Early results: \u201cRocket\u201d a Phase II Study of Rrx-001, a novel triple epigenetic inhibitor, resensitization to irinotecan in colorectal cancer. Ann. Oncol. 26, ii3 (2015).","DOI":"10.1093\/annonc\/mdv081.8"},{"key":"683_CR27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41416-019-0504-8","volume":"121","author":"D Morgensztern","year":"2019","unstructured":"Morgensztern, D. et al. RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer. Br. J. Cancer 121, 211\u2013217 (2019).","journal-title":"Br. J. Cancer"},{"key":"683_CR28","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.2217\/fon-2019-0317","volume":"15","author":"B Oronsky","year":"2019","unstructured":"Oronsky, B. et al. REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer. Future Oncol. 15, 3427\u20133433 (2019).","journal-title":"Future Oncol."},{"key":"683_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000443725","volume":"9","author":"CA Carter","year":"2016","unstructured":"Carter, C. A. et al. Partial response to platinum doublets in refractory EGFR-positive non-small cell lung cancer patients after RRx-001: evidence of episensitization. Case Rep. Oncol. 9, 62\u201367 (2016).","journal-title":"Case Rep. Oncol."},{"key":"683_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/13543784.2017.1268600","volume":"26","author":"B Oronsky","year":"2017","unstructured":"Oronsky, B. et al. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Expert Opin. Investig. Drugs 26, 109\u2013119 (2017).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"683_CR31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10637-016-0326-y","volume":"34","author":"B Oronsky","year":"2016","unstructured":"Oronsky, B. et al. RRx-001, a novel dinitroazetidine radiosensitizer. Invest N. Drugs 34, 371\u2013377 (2016).","journal-title":"Invest N. Drugs"},{"key":"683_CR32","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1124\/dmd.112.046755","volume":"40","author":"J Scicinski","year":"2012","unstructured":"Scicinski, J. et al. Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent. Drug Metab. Dispos. 40, 1810\u20131816 (2012).","journal-title":"Drug Metab. Dispos."},{"key":"683_CR33","doi-asserted-by":"publisher","first-page":"43172","DOI":"10.18632\/oncotarget.6526","volume":"6","author":"H Zhao","year":"2015","unstructured":"Zhao, H. et al. Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity. Oncotarget 6, 43172\u201343181 (2015).","journal-title":"Oncotarget"},{"key":"683_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-016-0220-7","volume":"8","author":"B Oronsky","year":"2016","unstructured":"Oronsky, B., Scicinski, J., Cabrales, P. & Minchinton, A. RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors. Clin. Epigenetics 8, 53 (2016).","journal-title":"Clin. Epigenetics"},{"key":"683_CR35","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.tranon.2018.12.001","volume":"12","author":"P Cabrales","year":"2019","unstructured":"Cabrales, P. RRx-001 acts as a dual small molecule checkpoint inhibitor by downregulating CD47 on cancer cells and SIRP-alpha on monocytes\/macrophages. Transl. Oncol. 12, 626\u2013632 (2019).","journal-title":"Transl. Oncol."},{"key":"683_CR36","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s00432-019-02958-4","volume":"145","author":"B Oronsky","year":"2019","unstructured":"Oronsky, B., Scribner, C., Aggarwal, R. & Cabrales, P. RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibition. J. Cancer Res Clin. Oncol. 145, 2045\u20132050 (2019).","journal-title":"J. Cancer Res Clin. Oncol."},{"key":"683_CR37","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S1470-2045(15)00089-3","volume":"16","author":"T Reid","year":"2015","unstructured":"Reid, T. et al. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Lancet Oncol. 16, 1133\u20131142 (2015).","journal-title":"Lancet Oncol."},{"key":"683_CR38","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.immuni.2016.08.010","volume":"45","author":"CJ Gross","year":"2016","unstructured":"Gross, C. J. et al. K+ efflux-independent NLRP3 inflammasome activation by small molecules targeting mitochondria. Immunity 45, 761\u2013773 (2016).","journal-title":"Immunity"},{"key":"683_CR39","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.molcel.2019.06.039","volume":"75","author":"W Yu","year":"2019","unstructured":"Yu, W. et al. One-carbon metabolism supports S-adenosylmethionine and histone methylation to drive inflammatory macrophages. Mol. Cell 75, 1147\u20131160 e1145 (2019).","journal-title":"Mol. Cell"},{"key":"683_CR40","first-page":"251","volume":"21","author":"B Oronsky","year":"2016","unstructured":"Oronsky, B. et al. RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells. Disco. Med 21, 251\u2013265 (2016).","journal-title":"Disco. Med"},{"key":"683_CR41","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/sj.cdd.4402195","volume":"14","author":"V Petrilli","year":"2007","unstructured":"Petrilli, V. et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 14, 1583\u20131589 (2007).","journal-title":"Cell Death Differ."},{"key":"683_CR42","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.immuni.2013.05.016","volume":"38","author":"R Munoz-Planillo","year":"2013","unstructured":"Munoz-Planillo, R. et al. K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38, 1142\u20131153 (2013).","journal-title":"Immunity"},{"key":"683_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12504","volume":"7","author":"MJ Daniels","year":"2016","unstructured":"Daniels, M. J. et al. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer\u2019s disease in rodent models. Nat. Commun. 7, 12504 (2016).","journal-title":"Nat. Commun."},{"key":"683_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00227-x","volume":"8","author":"T Tang","year":"2017","unstructured":"Tang, T. et al. CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation. Nat. Commun. 8, 202 (2017).","journal-title":"Nat. Commun."},{"key":"683_CR45","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nature09663","volume":"469","author":"R Zhou","year":"2011","unstructured":"Zhou, R., Yazdi, A. S., Menu, P. & Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221\u2013225 (2011).","journal-title":"Nature"},{"key":"683_CR46","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41423-020-0480-1","volume":"17","author":"JH Xie","year":"2020","unstructured":"Xie, J. H., Li, Y. Y. & Jin, J. The essential functions of mitochondrial dynamics in immune cells. Cell Mol. Immunol. 17, 712\u2013721 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"683_CR47","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.cell.2014.02.008","volume":"156","author":"A Lu","year":"2014","unstructured":"Lu, A. et al. Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes. Cell 156, 1193\u20131206 (2014).","journal-title":"Cell"},{"key":"683_CR48","doi-asserted-by":"crossref","unstructured":"Dick, M. S., Sborgi, L., Ruhl, S., Hiller, S. & Broz, P. ASC filament formation serves as a signal amplification mechanism for inflammasomes. Nat. Commun. 7, 11929 (2016).","DOI":"10.1038\/ncomms11929"},{"key":"683_CR49","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/nature16959","volume":"530","author":"Y He","year":"2016","unstructured":"He, Y., Zeng, M. Y., Yang, D., Motro, B. & Nunez, G. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature 530, 354\u2013357 (2016).","journal-title":"Nature"},{"key":"683_CR50","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/ni.3333","volume":"17","author":"HX Shi","year":"2016","unstructured":"Shi, H. X. et al. NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component. Nat. Immunol. 17, 250\u2013258 (2016).","journal-title":"Nat. Immunol."},{"key":"683_CR51","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1074\/jbc.C115.700492","volume":"291","author":"JL Schmid-Burgk","year":"2016","unstructured":"Schmid-Burgk, J. L. et al. A genome-wide CRISPR (clustered regularly interspaced short palindromic repeats) screen identifies NEK7 as an essential component of NLRP3 inflammasome activation. J. Biol. Chem. 291, 103\u2013109 (2016).","journal-title":"J. Biol. Chem."},{"key":"683_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9771","volume":"6","author":"T Haq","year":"2015","unstructured":"Haq, T. et al. Mechanistic basis of Nek7 activation through Nek9 binding and induced dimerization. Nat. Commun. 6, 8771 (2015).","journal-title":"Nat. Commun."},{"key":"683_CR53","doi-asserted-by":"publisher","first-page":"21984","DOI":"10.1073\/pnas.0910040106","volume":"106","author":"B Lomenick","year":"2009","unstructured":"Lomenick, B. et al. Target identification using drug affinity responsive target stability (DARTS). Proc. Natl Acad. Sci. USA 106, 21984\u201321989 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"683_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.redox.2015.07.002","volume":"6","author":"J Scicinski","year":"2015","unstructured":"Scicinski, J. et al. NO to cancer: the complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001. Redox Biol. 6, 1\u20138 (2015).","journal-title":"Redox Biol."},{"key":"683_CR55","doi-asserted-by":"publisher","first-page":"334","DOI":"10.4049\/jimmunol.1202737","volume":"190","author":"Y He","year":"2013","unstructured":"He, Y., Franchi, L. & Nunez, G. TLR agonists stimulate Nlrp3-dependent IL-1beta production independently of the purinergic P2X7 receptor in dendritic cells and in vivo. J. Immunol. 190, 334\u2013339 (2013).","journal-title":"J. Immunol."},{"key":"683_CR56","doi-asserted-by":"publisher","first-page":"974","DOI":"10.4049\/jimmunol.0904145","volume":"185","author":"D Gris","year":"2010","unstructured":"Gris, D. et al. NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J. Immunol. 185, 974\u2013981 (2010).","journal-title":"J. Immunol."},{"key":"683_CR57","doi-asserted-by":"publisher","first-page":"10480","DOI":"10.1073\/pnas.1201836109","volume":"109","author":"M Inoue","year":"2012","unstructured":"Inoue, M., Williams, K. L., Gunn, M. D. & Shinohara, M. L. NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA 109, 10480\u201310485 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"683_CR58","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41586-019-1295-z","volume":"570","author":"H Sharif","year":"2019","unstructured":"Sharif, H. et al. Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome. Nature 570, 338\u2013343 (2019).","journal-title":"Nature"}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41423-021-00683-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-021-00683-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-021-00683-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T11:02:42Z","timestamp":1675335762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-021-00683-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["683"],"URL":"https:\/\/doi.org\/10.1038\/s41423-021-00683-y","relation":{},"ISSN":["1672-7681","2042-0226"],"issn-type":[{"value":"1672-7681","type":"print"},{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,10]]},"assertion":[{"value":"4 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.Z., W.J. and Y.C. are named as inventors on China National Intellectual Property Administration Application Serial No. 202011472140.0 related to RRx-001.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}